Bryan Davies, PhD
Bryan completed his BSc in Biochemistry at McMaster University, PhD in Molecular Biology at MIT, and postdoctoral fellowship in infectious diseases at Harvard Medical School. He is an Associate Professor in the Departments of Molecular Biosciences and Medical Education. His research interests include investigating processes that enable microbes to engage with humans, and engineering biologics and synthetic cell-based systems to control these connections.
Jennifer Parker, MSc
Jennifer completed her MSc in Environmental Health at the University of Washington. She has conducted research in diverse disciplines including environmental microbiology, plant pathology, and public health microbiology. Her current work is focused on discovering novel naturally-occurring antimicrobial peptides (microcins), elucidating their role in modulating the host microbiome, and engineering bacterial delivery systems to provide microcin-based therapeutics.
Renee Fleeman, PhD
Renee earned her PhD from the University of South Florida where she worked discovering novel small molecule antimicrobials. Her current work focuses on obtaining a better understanding of the innate immune system evasion strategies used by Klebsiella pneumoniae and how we can use these interactions as targets for novel adjunctive therapeutics
Justin Randall, PhD
Justin earned his PhD at the University of Michigan studying bacterial DNA repair. He joined the Davies lab to pursue more translation research and is now developing peptide therapeutics targeting Vibrio cholerae.
Charles Gomes, PhD
Charles earned his PhD in Biotechnology from the Federal University of Pelotas, Brazil and did half of his graduate training at the University of Tennessee Health Science Center (UTHSC), Memphis, TN. His research was focused on the discovery of novel vaccine candidates and novel vaccine approaches to prophylactically treat a bacterial infection. After graduating, Charles joined UTHSC as a Senior Scientist where he studied the impact of the gut microbiome in metabolism and metabolic disorders. His current research is focused on Microbiome Therapeutics, using microorganisms to improve host colonization and using bacteria as delivery systems of small peptides targeting the brain, with a final goal of archiving behavior modulation, decrease response to pain and potentially treat some neurological conditions
Xun received her BSc in biology from Tsinghua University in Beijing, China. Since joining Davies lab, she developed an interest in using microbiology to pave a way towards drug development. She studied how A. baumannii survive on dry surfaces for extended periods and spread within hospitals. Her current focus is on screening and engineering of novel antimicrobials.
Greg received his BSc in Biology with emphasis on microbiology at the University of Texas at Austin. His previous work studied the mechanism of action of the antimicrobial benzalkonium chloride. His graduate work focuses on bacterial pathogen strategies for host colonization and species specific biologic approaches to addressing pathogen colonization and infection.
Cory is graduate student in the iCMB program. He uses statistics and computational modeling to analyze protein therapeutics and the disease causing microbes that they treat.
Colleen is a graduate student in the microbiology program. She works on the development of novel screening platforms for GPCRs.
Sun-Young Kim is from South Korea and majored in microbiology. He is interested in manipulating bacteria to make human lives better. Currently, he is engineering bacteria to secrete peptides as tools for delivery and biotechnology.
Ashley received her BSc in Human Biology from the University of Texas at Austin. Her research is focused on finding novel gut-specific therapeutics in order to treat bacterial gastrointestinal infections.
Santos completed his BSc in Human Biology from the University of Texas at Austin, with coursework focused on pathogenesis and immunity. His current work is aimed at identifying molecular motifs to optimize the pharmacokinetics of cationic antimicrobial peptides and mitigate their renal clearance.
Dr. Ashley Tucker – Scientist 1, Anexigen Inc
Dr. Andy Goodrich – Scientist 1, Anexigen Inc
Alex Crofts – Postdoctoral fellow, Southwestern Medical Center
Dr. Joe Boll – Assistant Professor, University of Texas Arlington
Aaron Conrado – Public Policy, Washington DC
Misha Kazi – graduate student, University of Texas Arlington
Cody Cole – graduate student University of Chicago
Dr. Donna Jones – visiting Professor
Nora Burdis – internal medicine resident, John Hopkins